Keyword: Michel Vounatsos
Spinraza and Zolgensma are in a closely watched market battle and early numbers show the meds might be able to grow sales alongside one another.
Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.
Biogen CEO Michel Vounatsos was richly rewarded last year but is now facing pressure to come up with a new R&D plan.
After its Alzheimer's drug flop wiped out 30% of Biogen's market cap, the company is adding three new members to its board.
After Biogen's Alzheimer's disease trial failure last month, executives are working to ease investor concern about the company's future.
Biogen CEO Michel Vounatsos totted up a healthy $13.6M last year, but will likely need some big R&D deals and wins to boost his 2018 pay package.
Biogen's Spinraza sales only increased modestly quarter-over-quarter, but there's still plenty of growth ahead, execs say.
George Scangos left Biogen on an up note, but the company has plenty of challenges ahead. For his final year as CEO, Scangos' total compensation added up to $17.73 million.
Every quarter, the FiercePharma team analyzes biopharma earnings reports and investor calls, and we're compiling the first quarter's here. Check back daily for updates.